Drug interactions between Actos and Nexavar
Results for the following 2 drugs: |
|
|---|---|
| Actos (pioglitazone) | |
| Nexavar (sorafenib) | |
Interactions between your selected drugs
pioglitazone ⇔ sorafenib
Applies to: Actos (pioglitazone) and Nexavar (sorafenib)
MONITOR: Coadministration with inhibitors of CYP450 2C8 may increase the plasma concentrations of pioglitazone, which is primarily metabolized by the isoenzyme. In ten healthy volunteers, pretreatment with the potent CYP450 2C8 inhibitor gemfibrozil (600 mg twice daily) for two days prior to coadministration of gemfibrozil and pioglitazone (30 mg orally) resulted in pioglitazone systemic exposure (AUC) that was 226% of that observed without gemfibrozil.
MANAGEMENT: Given the potential for dose-related adverse events with pioglitazone, caution is advised during coadministration with CYP450 2C8 inhibitors. Close monitoring for the development of hypoglycemia and other adverse effects of pioglitazone such as fluid retention, heart failure, and pulmonary and peripheral edema is recommended. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations. The physician should be notified if an interaction is suspected.
See also...
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2009 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
